Yu Chun-Yang, Gu Yang, Jiang Yi-Cheng, Zhang Xi-Wen
Department of Cardiology, First Affiliated Hospital, Nanjing Medical University, Huai'an City, China.
Front Cardiovasc Med. 2022 Oct 6;9:992284. doi: 10.3389/fcvm.2022.992284. eCollection 2022.
The purpose of the present article is to identify intrinsic genes across general hypertension (HT), hypertension with left ventricular remodeling (HT-LVR), and uncontrolled hypertension (UN-HT). In total, four microarray datasets (GSE24752, GSE75360, GSE74144, and GSE71994) were downloaded from the GEO database and were used to identify differentially expressed genes (DEGs), respectively. Furthermore, gene set enrichment analysis (GSEA) was utilized to screen for significantly enriched biological pathways across the four datasets above, respectively. Furthermore, weighted gene co-expression network analysis (WGCNA) and functional enrichment analysis were applied to screen out gene modules of interest and potential biological functions, respectively. Finally, a Metascape-based multiple gene list meta-analysis was used to investigate intrinsic genes at different stages of the progression of hypertension. A total of 75 DEGs (63 upregulated genes and 12 downregulated genes, GSE24752) and 23 DEGs (2 upregulated genes and 21 downregulated genes, GSE74144) were identified. However, there were few DEGs identified in GSE75360, GSE71994, and part of the GSE74144 datasets. GSEA and functional enrichment of gene module of interest have indicated that "Heme metabolism," "TNF alpha/NFkB," and "interferon alpha response signaling," and MYC target v1/v2 were enriched significantly in different stages of hypertension progression. Significantly, findings from the multiple gene list meta-analysis suggested that and other 13 genes were unique to the hypertension group, and and other 40 genes were mainly involved in hypertension with the left ventricular remodeling group, while the other 18 genes including significantly enriched in uncontrolled hypertension. Collectively, the precise switch of the "immune-metabolic-inflammatory" loop pathway was the most significant hallmark across different stages of hypertension, thereby providing a potential therapeutic target for uncontrolled hypertension treatment.
本文的目的是识别普通高血压(HT)、伴有左心室重塑的高血压(HT-LVR)和未控制的高血压(UN-HT)中的内在基因。总共从基因表达综合数据库(GEO数据库)下载了四个微阵列数据集(GSE24752、GSE75360、GSE74144和GSE71994),并分别用于识别差异表达基因(DEG)。此外,基因集富集分析(GSEA)分别用于筛选上述四个数据集中显著富集的生物途径。此外,加权基因共表达网络分析(WGCNA)和功能富集分析分别用于筛选感兴趣的基因模块和潜在的生物学功能。最后,基于Metascape的多基因列表荟萃分析用于研究高血压进展不同阶段的内在基因。共鉴定出75个差异表达基因(63个上调基因和12个下调基因,GSE24752)和23个差异表达基因(2个上调基因和21个下调基因,GSE74144)。然而,在GSE75360、GSE71994以及部分GSE74144数据集中鉴定出的差异表达基因较少。感兴趣的基因模块的基因集富集分析和功能富集表明,“血红素代谢”“肿瘤坏死因子α/核因子κB”和“干扰素α反应信号”以及MYC靶标v1/v2在高血压进展的不同阶段显著富集。值得注意的是,多基因列表荟萃分析的结果表明,[此处原文缺失具体基因名称]和其他13个基因是高血压组特有的,[此处原文缺失具体基因名称]和其他40个基因主要涉及伴有左心室重塑的高血压组,而包括[此处原文缺失具体基因名称]在内的其他18个基因在未控制的高血压中显著富集。总的来说,“免疫-代谢-炎症”循环途径的精确转换是高血压不同阶段最显著的标志,从而为未控制的高血压治疗提供了一个潜在的治疗靶点。